This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Stocks Under $5 With Upside

PURE Bioscience develops and commercializes bioscience technologies. The company's flagship bioscience technology is an aqueous antimicrobial called silver dihydrogen citrate (SDC). Of the two analysts covering the stock, 50% recommend a buy while the remaining rate holding. As per the consensus estimates of analysts polled by Bloomberg, the stock has an implied upside of 161.2% and is currently trading at $2.01.

Richmont Sciences, PURE's marketing agent, has secured a 10-year, $144 million supply contract from High Scope, a Middle East distributor. The deal's major objective is to bring SDC-based water treatment to the nine Middle East countries. A $355,000 worth product shipment, initially to be used in Dubai as a short trial, launched the 10-year commitment. Meanwhile, High Scope has agreed to buy a minimum $9 million worth SDC in 2011 with annual purchases increasing to $21 million during the tenth year.

The U.S Environmental Protection Agency has approved Pure's SDC as a food-contact surface sanitizer, which opens up new markets. To reduce the threat of bacterial contamination of poultry products, the company is working closely with food microbiologists for testing SDC as a carcass wash. The poultry sector presents a robust growth opportunity and PURE is due to conduct a large study at the University of Georgia, which maintains a facility of almost 9 million chickens.

Griffin Securities estimates the company reporting revenue of $1.9 million in the household product line, $752,000 in personal care and $500,000 in agriculture. Heading into 2012, revenue from these segments is likely to increase more than 90% from the 2011 levels.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CMFO $0.07 0.00%
PURE $0.73 0.00%
JMBA $15.20 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs